Semaglutide and TyG Index Linked to Dementia Risk

Researchers have discovered that semaglutide, a diabetes and weight-loss medication, significantly lowers the risk of dementia, especially Alzheimer's disease, in individuals with type 2 diabetes, with the strongest effects seen in women and older adults. The study, analyzing nearly 1.7 million patients over three years, shows semaglutide outperforms other antidiabetic drugs in reducing dementia risk. Separately, research presented at the European Academy of Neurology Congress 2025 demonstrates that the triglyceride-glucose (TyG) index, a routine blood test for insulin resistance, can identify Alzheimer's patients at four times higher risk of rapid cognitive decline. The TyG index is particularly predictive during the mild cognitive impairment stage of Alzheimer's disease. Both findings highlight the importance of metabolic health in managing dementia risk and progression. Early intervention through medication or metabolic monitoring is emphasized as a promising approach to slowing dementia onset.